Creative Medical Technology Holdings Inc (CELZ) Stock Price, Quote & News

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized super...

Industry: Biotechnology

Sector: Healthcare

Phone: 480 399 2822

Website: www.creativemedicaltechnology.com

Address:

211 East Osborn Road, Phoenix, United States

H177 Apr. 2 at 6:47 PM

$CELZ I can't wait till May.

1 · Reply

tonneke Apr. 2 at 5:21 PM

$CELZ

0 · Reply

H177 Mar. 31 at 7:54 PM

$CELZ

0 · Reply

H177 Mar. 31 at 6:45 PM

$CELZ

0 · Reply

CG2260 Mar. 31 at 3:21 PM

$CELZ

0 · Reply

Kjstock Mar. 27 at 2:04 PM

$CELZ I wasn’t around yesterday and this morning I noticed yesterday’s volume and price jump and I was curious to know if anything was up. So as lame as it maybe I ai- googled Celz..Not sure when they will say something but May is getting close! “1. Chronic Lower Back Pain (ADAPT Trial) The ADAPT Phase I/II trial for CELZ-201 (Olastrocel) is the company’s most advanced program. Current Status: Patient enrollment was successfully completed in December 2025. Interim Results: Data released in January 2026 showed a 79% success rate in achieving clinically meaningful functional improvement and pain reduction at 180 days. Next Milestones: Primary Completion: Estimated for May 1, 2026. Topline Results: Full data readout is expected in the first half of 2026. Regulatory Edge: The program has received FDA Fast Track Designation, which may accelerate its path to commercialization.

2 · Reply

tonneke Mar. 26 at 6:47 PM

$CELZ 💪

0 · Reply

TradersTrader Mar. 24 at 11:25 PM

$TSOI Whatever happened to the $5 million cash $CELZ gave Amit N. Patel for access to his “tool box”? What for? An exclusive license?? I don’t see anything specific for the $5 mil. Tim Warbington would know… We had a CELZ goon visit our board today. Not nice! Maybe I’ll dig into my Patel/CELZ/Narkesheyo file? Here you go! https://narkeshyo.com/ https://www.sec.gov/ix?doc=/Archives/edgar/data/1187953/000147793223005935/celz_10q.htm *Pg 14 - 5 million 💰 For what??? 🤔 Any Co willing to hire Camillo “I never read the patent “ Ricordi as PI for any trial, 😑 - AFTER he as PI spent 20 million on a 24 patient 2020 Covid/ARDS trial - lied under oath in IPR brought by his pals at Restem, as did Patel - Ricordi was then BOOTED by TSOI AS PI 🙌 $$$$$ just DISAPPEARS and mayhem ensues around those 2 weasels. I wish it was merely incompetence. Sorry, no. The lying and threats are a big red flag 🚩 Warbington should tell his mutt to return home. Friendly advice.

1 · Reply

wokazn Mar. 24 at 7:09 PM

$CELZ @CelzMates https://youtu.be/yHD1LTavOFM?si=kHyZgqXn6xbEzkCE

1 · Reply

Kjstock Mar. 20 at 8:46 PM

$CELZ Maybe we get something next week, volume perked up today!

1 · Reply

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

Jan 6, 2026, 9:15 AM EST - 3 months ago

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

Dec 17, 2025, 9:15 AM EST - 3 months ago

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

Dec 2, 2025, 9:15 AM EST - 4 months ago

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

Oct 30, 2025, 9:15 AM EDT - 5 months ago

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Oct 29, 2025, 9:00 AM EDT - 5 months ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

Oct 27, 2025, 8:15 AM EDT - 5 months ago

Creative Medical Technology Holdings Issues Letter to Shareholders

Oct 7, 2025, 9:15 AM EDT - 6 months ago

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

Jul 17, 2025, 9:15 AM EDT - 9 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

Jul 11, 2025, 8:01 AM EDT - 9 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

Mar 20, 2025, 7:50 AM EDT - 1 year ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

Mar 6, 2025, 8:10 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

Feb 14, 2025, 7:00 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Feb 11, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Feb 5, 2025, 8:25 AM EST - 1 year ago

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Jan 30, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Nov 13, 2024, 9:00 AM EST - 1 year ago

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Jul 24, 2024, 9:00 AM EDT - 1 year ago

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Jul 10, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Provides Corporate Update

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Mar 7, 2024, 9:15 AM EST - 2 years ago

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Mar 6, 2024, 7:00 AM EST - 2 years ago

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Dec 20, 2023, 9:35 AM EST - 2 years ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

Aug 24, 2023, 10:45 AM EDT - 2 years ago

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

Jul 14, 2023, 9:00 AM EDT - 2 years ago

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Jun 28, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Jun 12, 2023, 8:01 AM EDT - 3 years ago

Creative Medical Technology Announces $2 Million Share Repurchase Program

Jun 9, 2023, 12:30 PM EDT - 3 years ago

Creative Medical Technology Holdings Announces Reverse Stock Split

May 31, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

May 22, 2023, 8:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

May 18, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Apr 12, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Mar 23, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Mar 21, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Mar 7, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Feb 14, 2023, 8:00 AM EST - 3 years ago

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Feb 8, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Jul 28, 2022, 7:30 AM EDT - 4 years ago

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Jun 15, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

Apr 29, 2022, 8:40 AM EDT - 4 years ago

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 20, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Apr 12, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

Mar 23, 2022, 10:15 AM EDT - 4 years ago

Why Creative Medical Technology Shares Are Soaring

H177 Apr. 2 at 6:47 PM

$CELZ I can't wait till May.

1 · Reply

tonneke Apr. 2 at 5:21 PM

$CELZ

0 · Reply

H177 Mar. 31 at 7:54 PM

$CELZ

0 · Reply

H177 Mar. 31 at 6:45 PM

$CELZ

0 · Reply

CG2260 Mar. 31 at 3:21 PM

$CELZ

0 · Reply

Kjstock Mar. 27 at 2:04 PM

2 · Reply

tonneke Mar. 26 at 6:47 PM

$CELZ 💪

0 · Reply

TradersTrader Mar. 24 at 11:25 PM

1 · Reply

wokazn Mar. 24 at 7:09 PM

$CELZ @CelzMates https://youtu.be/yHD1LTavOFM?si=kHyZgqXn6xbEzkCE

1 · Reply

Kjstock Mar. 20 at 8:46 PM

$CELZ Maybe we get something next week, volume perked up today!

1 · Reply

Peterb3346 Mar. 18 at 11:24 AM

$CELZ what's that mean?

1 · Reply

H177 Mar. 18 at 8:04 AM

$CELZ

0 · Reply

H177 Mar. 17 at 7:43 AM

$CELZ

0 · Reply

AllinOneinAll Mar. 16 at 5:35 PM

$CELZ is this company any good ? 🤔

1 · Reply

tonneke Mar. 16 at 9:55 AM

$CELZ are we still on course or on a disaster course 🤷‍♂️🤷‍♂️🤷‍♂️

0 · Reply

wokazn Mar. 12 at 2:59 PM

$CELZ when will Tim call Celz a longevity company? Before the end of the year is my answer! https://time.com/7381303/aging-medicine-disease-arpa-h-longevity/

2 · Reply

OfficialStocktwitsUser Mar. 11 at 12:37 AM

$CELZ RSI: 50.00, MACD: -0.0310 Vol: 0.05, MA20: 1.86, MA50: 1.97 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

tonneke Mar. 8 at 2:23 PM

$CELZ The current analyst forecast (as of early 2026) for Creative Medical Technology Holdings (CELZ) shows a very high, unsubstantiated price target of around $20.00 to $21.00 USD. However, the actual trading price in February 2026 was actually lower, around $1.78-$1.89.

2 · Reply

BillionerOfKing Mar. 4 at 5:01 PM

$CELZ Current Stock Price: $1.77

1 · Reply

uppons Mar. 3 at 7:38 PM

$CELZ tough

0 · Reply

CookedHam1 Feb. 28 at 3:49 PM

$CELZ sell a hundred shares and buy 5000 of $AMFN i dont think you regret it. Just a suggestion not advice. Cheers Happy weekend

1 · Reply

Bobby_J_Bomb Feb. 28 at 3:05 PM

$CELZ Topline results expected in 1H26. If this looks good to go to phase 3, the partnership or acquisition prospects will skyrocket.

0 · Reply

Market Cap	7.59M
Revenue (ttm)	10,000.00
Net Income (ttm)	-6.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60,000.00%
Debt to Equity Ratio	0.00

Volume	4,200
Avg Vol	27,056
Day's Range	N/A - N/A
Shares Out	3.70M
Stochastic %K	85%
Beta	1.94
Analysts	Sell
Price Target	$20.00